Seminars in Fetal & Neonatal Medicine
Volume 11, Issue 2 , Pages 105-110 , April 2006

The role of neonatal networks

  • Marta Thakkar

      Affiliations

    • 3070 North 51st Street #P309, Milwaukee, WI 53210-1661, USA
    • ,
  • Michael O'Shea

      Affiliations

    • Department of Pediatrics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 336 716 2529; fax: +1 336 716 2525.

References 

  1. Silverman WA. The lesson of retrolental fibroplasia. Sci Am. 1977;236:100–107
  2. Hill GB. Archie Cochrane and his legacy. An internal challenge to physicians' autonomy?. J Clin Epidemiol. 2000;53:1189–1192
  3. Silverman WA. Human experimentation: a guided step into the unknown. Oxford: Oxford University Press; 1985;
  4. In:  Sinclair JC,  Bracken MB editor. Effective care of the newborn infant. Oxford: Oxford University Press; 1992;
  5. McWilliams R, Hoover-Fong J, Hamosh A, Beck S, Beaty T, Cutting G. Problematic variation in local institutional review of a multicenter genetic epidemiology study. JAMA. 2003;290:360–366
  6. Kraemer HC. Pitfalls of multi-site randomized clinical trials. Schizophr Bull. 2000;26:533–541
  7. Friedman LM, Furberg CD, DeMets DL. Multicenter trials. Fundamentals of clinical trials. New York: Springer; 1998;p. 345–56
  8. Weinberger M, Oddone EZ, Henderson WG, Smith DM, Huey J, Giobbie-Hurder A, et al. Multi-site randomized controlled trials in health services research: Scientific challenges and operational issues. Med Care. 2001;39:627–634
  9. Dewa CS, Durbin J, Wasylenki D, Ochocka J, Eastabrook S, Boydell KM, et al. Considering a multi-site study? How to take the leap and have a soft landing. J Commun Psychol. 2002;30:173–187
  10. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248–254
  11. Thom EA, Rouse DJ. What we have learned about conducting randomized controlled trials in the NICHD MFMU network. Semin Perinatol. 2003;27:253–260
  12. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 1999;340:1962–1968
  13. Ambalavanan N, Tyson JE, Kennedy KA, Hansen NI, Vohr BR, Wright LL, et al. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics. 2005;115:e249–e254
  14. Wilson JM, Bower LK, Thompson JE, Fauza DO, Fackler JC. ECMO in evolution: the impact of changing patient demographics and alternative therapies on ECMO. J Pediatr Surg. 1996;31:1116–1122
  15. Bennett CC, Johnson A, Field DJ, Elbourne D. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years. Lancet. 2001;357:1094–1096
  16. UK Collaborative ECMO Trail Group. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet. 1996;348:75–82
  17. Gold JL, Dewa CS. Institutional review boards and multi-site studies in health services research: Is there a better way?. Health Serv Res. 2005;40:291–307
  18. Silverman H, Hull SC, Sugarman J. Variability among institutional review boards' decisions within the context of a multicenter trial. Crit Care Med. 2001;29:235–241
  19. Vohr BR, O'Shea M, Wright LL. Longitudinal multicenter follow-up of high-risk infants: Why, who, when, and what to assess. Semin Perinatol. 2003;27:333–342
  20. Kuban K, O'Shea M. Standardizing the 1-year neurological exam for the Extremely Low Gestational Age Neonate (ELGAN) 14-center study—A multimedia solution?. Ann Neurol. 2004;56:S111
  21. Brown AK, Kim MH, Wu PYK, Bryla DA. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics. 1985;75(Suppl.):387–392
  22. Peckham GJ, Miettinen OS, Ellison RC, Kraybill EN, Gersony WM, Zierler S, et al. Clinical Course to 1-year-of-age in premature-infants with patent ductus-arteriosus—results of a multicenter randomized trial of indomethacin. J Pediatr. 1984;105:285–291
  23. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory-distress syndrome. Am J Obstet Gynecol. 1981;141:276–287
  24. Ehrenkranz RA, Wright LL. NICHD Neonatal Research Network: contributions and future challenges. Semin Perinatol. 2003;27:264–280
  25. Tyson JE, Wright LL, Oh WOM, Kennedy KA, Mele L, Ehrenkranz RA, et al. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med. 1999;340:1962–1968
  26. Carlo WA, Stark AR, Bauer C, Donovan E, Oh W, Papile LA, et al. Effects of minimal ventilation in a multicenter randomized controlled trial of ventilator support and early corticosteroid therapy in extremely low birth weight infants. Pediatrics. 1999;104:738–739
  27. Van Meurs K, Wright LL, Ehrenkrans RA, Lemon JA, Ball B, Poole WK, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005;353:13–22
  28. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001;344:1966–1972
  29. Edwards WH, Conner JM, Soll RF. The effect of prophylactic ointment therapy on nosocomial sepsis rates and skin integrity in infants with birth weights of 501 to 1000g. Pediatrics. 2004;113:1195–1203
  30. Anderson ME, Bednarek FJ, Dreyer G, Magoon MW, Mercier CE, Soll RF, et al. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics. 2001;108:741–748
  31. Flynn JT. An international classification of retinopathy of prematurity—clinical Experience. Ophthalmology. 1985;92:987–994
  32. Kuban K, Teele RL. Rationale for Grading Intracranial Hemorrhage in Premature-Infants. Pediatrics. 1984;74:358–363
  33. Paneth N, Qiu H, Rosenbaum P, Saigal S, Bishai S, Jetton J, et al. Reliability of classification of cerebral palsy in low-birthweight children in four countries. Dev Med Child Neurol. 2003;45:628–633
  34. Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol. 2000;42:816–824
  35. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 2004;114:1305–1311
  36. Nelson KB, Ellenberg JH. Antecedents of cerebral-palsy—multivariate-analysis of Risk. N Engl J Med. 1986;315:81–86
  37. Ellenberg JH, Nelson KB. Cluster of perinatal events identifying infants at high-risk for death or disability. J Pediatr. 1988;113:546–552
  38. Nelson KB, Ellenberg JH. Children who outgrew cerebral palsy. Pediatrics. 1982;69:529–536
  39. Stanley F, Blair E, Alberman E. Cerebral palsies: epidemiology and causal inference. London: MacKeith; 2000;
  40. Paneth N, Rudelli R, Kazam E, Monte W. Brain damage in the preterm infant. London: MacKeith Press; 1994;
  41. Leviton A, Paneth N, Reuss ML, Susser M, Allred EN, Dammann O, et al. Maternal infection, fetal inflammatory response, and brain damage in very low birth weight infants. Pediatr Res. 1999;46:566–575
  42. Kitchen WH, Orgill A, Rickards A, Ryan MM, Lissenden JV, Keith CG, et al. Collaborative study of very low-birth-weight infants—outcome of 2-year-old survivors. Lancet. 1982;1:1457–1460
  43. van Zeben-van Der TM, Verloove-Vanhorick SP, Brand R, Ruys JH. Morbidity of very low birthweight infants at corrected age of two years in a geographically defined population. Lancet. 1989;253–255
  44. Walther FJ, den Ouden AL, Verloove-Vanhorick SP. Looking back in time: outcome of a national cohort of very preterm infants born in The Netherlands in 1983. Early Hum Dev. 2000;59:175–191
  45. Leviton A, Baglivo J, Kuban KCK, Brown ER, Krishnamoorthy KC. The prophylactic clinical trial as an epidemiologic resource. Control Clin Trials. 1987;8:243–254
  46. Leviton A, Kuban KCK, Pagano M, Brown ER, Krishnamoorthy KS, Allred EN. Maternal toxemia and neonatal germinal matrix hemorrhage in intubated infants less than 1751-g. Obstet Gynecol. 1988;72:571–576
  47. Allan WC, Vohr B, Makuch RW, Katz KH, Ment LR. Antecedents of cerebral palsy in a multicenter trial of indomethacin for intraventricular hemorrhage. Arch Pediatr Adolesc Med. 1997;151:580–585
  48. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA. 2004;292:2357–2365
  49. Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993–1994. Pediatrics. 2000;105:1216–1226
  50. Oh W, Tyson JE, Fanaroff AA, Vohr BR, Perritt R, Stoll BJ, et al. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics. 2003;112:773–779
  51. Vermont Oxford Network . http://www.vtoxford.org2005;
  52. Horbar JD. The Vermont Oxford Network: evidence-based quality improvement for neonatology. Pediatrics. 1999;103:350–359
  53. Horbar JD, Rogowski J, Plsek PE, Delmore P, Edwards WH, Hocker J, et al. Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network. Pediatrics. 2001;107:14–22
  54. Lisonkova S, Lee SK, Bavinton HB, Sarabia M. The Canadian Neonatal Network 2003. Annual report. 2003;3:

PII: S1744-165X(05)00099-5

doi: 10.1016/j.siny.2005.11.003

Seminars in Fetal & Neonatal Medicine
Volume 11, Issue 2 , Pages 105-110 , April 2006

Article Tools